
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2008264/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	ldentification of asymptomatic Entamoeba histolytica infection by a serological screening test: A cross-sectional study of an HIV-negative men who have sex with men cohort in Japan. PLoS Neglected Tropical Diseases, 2022, 16, e0009793.	3.0	4
2	High prevalence of circulating dual-class resistant <i>Mycoplasma genitalium</i> in asymptomatic MSM in Tokyo, Japan. JAC-Antimicrobial Resistance, 2021, 3, dlab091.	2.1	13
3	Performance of an enzyme-linked immunosorbent-based serological assay for Entamoeba histolytica: Comparison with an indirect immunofluorescence assay using stored frozen samples. Journal of Infection and Chemotherapy, 2021, 27, 736-739.	1.7	3
4	Long-term weight gain after initiating combination antiretroviral therapy in treatment-naÃ ⁻ ve Asian people living with human immunodeficiency virus. International Journal of Infectious Diseases, 2021, 110, 21-28.	3.3	19
5	Modified self-obtained pooled sampling to screen for <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> infections in men who have sex with men. Sexually Transmitted Infections, 2021, 97, 324-328.	1.9	9
6	Seroprevalence of <i>Entamoeba histolytica</i> at a voluntary counselling and testing centre in Tokyo: a cross-sectional study. BMJ Open, 2020, 10, e031605.	1.9	10
7	Fullâ€genome analysis of hepatitis C virus in HIVâ€coinfected hemophiliac Japanese patients. Hepatology Research, 2020, 50, 763-769.	3.4	1
8	Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up. Global Health & Medicine, 2020, 2, 9-17.	1.4	6
9	Title is missing!. , 2020, 16, e1009177.		0
10	Title is missing!. , 2020, 16, e1009177.		0
11	Title is missing!. , 2020, 16, e1009177.		0
12	Title is missing!. , 2020, 16, e1009177.		0
13	Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study. Journal of Antimicrobial Chemotherapy, 2019, 74, 3402-3403.	3.0	1
14	High prevalence and incidence of rectal ChlamydiaÂinfection among men who have sex with men in Japan. PLoS ONE, 2019, 14, e0220072.	2.5	11
15	Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 350-357.	2.1	8
16	Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease. Journal of Infection and Chemotherapy, 2018, 24, 549-554.	1.7	12
17	Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut, 2018, 67, 362-371.	12.1	144
18	Time to development of ocular syphilis after syphilis infection. Journal of Infection and Chemotherapy, 2018, 24, 75-77.	1.7	14

#	Article	IF	CITATIONS
19	Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study. BMC Cancer, 2018, 18, 1066.	2.6	27
20	Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control. EBioMedicine, 2018, 36, 103-112.	6.1	10
21	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. Aids, 2017, 31, 1935-1943.	2.2	7
22	Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors. PLoS ONE, 2017, 12, e0177033.	2.5	10
23	Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. PLoS ONE, 2017, 12, e0186255.	2.5	13
24	HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-Câ^—12:02/Câ^—14:03. Cell Reports, 2016, 17, 2210-2220.	6.4	27
25	Effects of a Single Escape Mutation on T Cell and HIV-1 Co-adaptation. Cell Reports, 2016, 15, 2279-2291.	6.4	19
26	Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. Journal of Antimicrobial Chemotherapy, 2016, 71, 2760-2766.	3.0	6
27	Lack of a significant impact of Cag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Retrovirology, 2015, 12, 98.	2.0	4
28	Routine Eye Screening by an Ophthalmologist Is Clinically Useful for HIV-1-Infected Patients with CD4 Count Less than 200 /Î1⁄4L. PLoS ONE, 2015, 10, e0136747.	2.5	27
29	Prevalence of Anal Human Papillomavirus Infection and Risk Factors among HIV-positive Patients in Tokyo, Japan. PLoS ONE, 2015, 10, e0137434.	2.5	27
30	A 21-Day of Adjunctive Corticosteroid Use May Not Be Necessary for HIV-1-Infected Pneumocystis Pneumonia with Moderate and Severe Disease. PLoS ONE, 2015, 10, e0138926.	2.5	5
31	What Triggers a Diagnosis of HIV Infection in the Tokyo Metropolitan Area? Implications for Preventing the Spread of HIV Infection in Japan. PLoS ONE, 2015, 10, e0143874.	2.5	9
32	HIV-1 infection, but not syphilis or HBV infection, is a strong risk factor for anorectal condyloma in Asian population: A prospective colonoscopy screening study. International Journal of Infectious Diseases, 2015, 37, 70-76.	3.3	4
33	Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections. Journal of Virology, 2015, 89, 7363-7372.	3.4	5
34	High-Dose Oral Amoxicillin Plus Probenecid Is Highly Effective for Syphilis in Patients With HIV Infection. Clinical Infectious Diseases, 2015, 61, 177-183.	5.8	49
35	Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes. Journal of Virology, 2015, 89, 5330-5339.	3.4	56
36	Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study. PLoS ONE, 2015, 10, e0141931.	2.5	6

#	Article	IF	CITATIONS
37	Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection. PLoS ONE, 2014, 9, e87596.	2.5	42
38	Acute Hepatitis C in HIV-1 Infected Japanese Cohort: Single Center Retrospective Cohort Study. PLoS ONE, 2014, 9, e100517.	2.5	18
39	Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. Journal of Antimicrobial Chemotherapy, 2014, 69, 3320-3328.	3.0	15
40	Clinical Significance of High Anti-Entamoeba histolytica Antibody Titer in Asymptomatic HIV-1-infected Individuals. Journal of Infectious Diseases, 2014, 209, 1801-1807.	4.0	24
41	Clinical Importance of Hyper-Beta-2-Microglobulinuria in Patients With HIV-1 Infection on Tenofovir-Containing Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e155-e157.	2.1	3
42	Selection of TI8-8V Mutant Associated with Long-Term Control of HIV-1 by Cross-Reactive HLA-B*51:01–Restricted Cytotoxic T Cells. Journal of Immunology, 2014, 193, 4814-4822.	0.8	11
43	Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition. Microbes and Infection, 2014, 16, 434-438.	1.9	1
44	Asymptomatic Intestinal Amebiasis in Japanese HIV-1–Infected Individuals. American Journal of Tropical Medicine and Hygiene, 2014, 91, 816-820.	1.4	10
45	Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study. Journal of Infection and Chemotherapy, 2014, 20, 784-788.	1.7	13
46	Superimposed Epitopes Restricted by the Same HLA Molecule Drive Distinct HIV-Specific CD8+ T Cell Repertoires. Journal of Immunology, 2014, 193, 77-84.	0.8	15
47	Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population. Journal of Virology, 2014, 88, 4764-4775.	3.4	47
48	Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting. Journal of Infection and Chemotherapy, 2014, 20, 285-287.	1.7	8
49	Incidence and Risk Factors for Incident Hepatitis C Infection Among Men Who Have Sex With Men With HIV-1 Infection in a Large Urban HIV Clinic in Tokyo. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 213-217.	2.1	58
50	Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity. Clinical Infectious Diseases, 2013, 57, 1051-1055.	5.8	22
51	Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. Clinical Infectious Diseases, 2013, 56, 1812-1819.	5.8	61
52	Distinct HIV-1 Escape Patterns Selected by Cytotoxic T Cells with Identical Epitope Specificity. Journal of Virology, 2013, 87, 2253-2263.	3.4	30
53	Reply to Sheng et al. Clinical Infectious Diseases, 2013, 57, 1506-1506.	5.8	10
54	Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-NaÃ ⁻ ve Patients with Advanced HIV-1 Infection in the HAART Era. PLoS ONE, 2013, 8, e65348.	2.5	15

#	Article	IF	CITATIONS
55	Illicit Drug Use Is a Significant Risk Factor for Loss to Follow Up in Patients with HIV-1 Infection at a Large Urban HIV Clinic in Tokyo. PLoS ONE, 2013, 8, e72310.	2.5	13
56	Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients. PLoS ONE, 2013, 8, e77268.	2.5	17
57	Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?. PLoS ONE, 2013, 8, e69845.	2.5	10
58	High Prevalence of Illicit Drug Use in Men Who Have Sex with Men with HIV-1 Infection in Japan. PLoS ONE, 2013, 8, e81960.	2.5	17
59	HLA Class I-Mediated Control of HIV-1 in the Japanese Population, in Which the Protective HLA-B*57 and HLA-B*27 Alleles Are Absent. Journal of Virology, 2012, 86, 10870-10872.	3.4	40
60	High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy. Clinical Infectious Diseases, 2012, 55, 1262-1269.	5.8	80
61	Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naà ve Patients with HIV Infection. PLoS ONE, 2012, 7, e29977.	2.5	54
62	Selection of escape mutant by HLAâ€Câ€restricted HIVâ€1 Polâ€specific cytotoxic T lymphocytes carrying strong ability to suppress HIVâ€1 replication. European Journal of Immunology, 2011, 41, 97-106.	2.9	26
63	Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-Bâ^—4002-restricted T cells. Microbes and Infection, 2011, 13, 160-166.	1.9	10
64	Amebiasis in HIV-1-Infected Japanese Men: Clinical Features and Response to Therapy. PLoS Neglected Tropical Diseases, 2011, 5, e1318.	3.0	56
65	Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. Aids, 2010, 24, F15-F22.	2.2	13
66	Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan. Antiviral Research, 2010, 88, 72-79.	4.1	50
67	Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but Not Etravirine. Antimicrobial Agents and Chemotherapy, 2010, 54, 1596-1602.	3.2	31
68	Adaptation of HIV-1 to human leukocyte antigen class I. Nature, 2009, 458, 641-645.	27.8	408
69	Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japanâ~†. Antiviral Research, 2007, 75, 75-82.	4.1	46
70	Altered HIV-1 Gag Protein Interactions with Cyclophilin A (CypA) on the Acquisition of H219Q and H219P Substitutions in the CypA Binding Loop. Journal of Biological Chemistry, 2006, 281, 1241-1250.	3.4	47